Reclaiming the name 'bronchiectasis'

Thorax

Volumn 70, Issue 5, 2015, Pages 399-400

  Chalmers, James D ^a   Elborn, J Stuart ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

BRONCHIECTASIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DECISION MAKING; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG TOLERABILITY; EDITORIAL; HEALTH CARE; HISTOPATHOLOGY; HUMAN; MORBIDITY; PRIORITY JOURNAL; SMALL AIRWAY DISEASE; THORAX RADIOGRAPHY; UNITED KINGDOM; COMPLICATION; NOMENCLATURE;

BRONCHIECTASIS; CYSTIC FIBROSIS; HUMANS; TERMINOLOGY AS TOPIC;

EID: 84929469223     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-206956     Document Type: Editorial

References (20)

1. Fitzgerald JM. Targeting lung attacks. Thorax 2011;66:365-6.
2. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003;14:488-92.
3. Chalmers JD, McHugh BJ, Doherty CJ, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in non-CF bronchiectasis. Thorax 2012;68:39-47.
4. Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. Plos ONE 2013;8: e71109.
5. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-9.
6. Bronchiectasis. The European Lung White Book 2014;15:176-83.
7. Lavery K, O'Neill B, Elborn JS, et al. Self-management in bronchiectasis: the patients' perspective. Eur Respir J 2007;29:541-7.
8. O'Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-34.
9. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2:738-49.
10. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014;69:1073-9.
11. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189:975-82.
12. Gaillard EA, Carty H, Heaf D, et al. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. J Radiol 2003;47:215-20.
13. Yap VL, Metersky ML. Reversible bronchiectasis in an adult: a case report. J Bronchology Interv Pulmonol 2012;19:336-7.
14. Hurst JR, Elborn JS, Soyza AD. COPD-Bronchiectasis overlap syndrome. Eur Respir J 2015;45:310-3.
15. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009;136:1521-8.
16. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65 (Suppl 1):i1-58.
17. Chalmers JD, Goeminne P, Aliberti S, et al. Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. Am J Respir Crit Care Med 2014;189:576-85.
18. Taylor RF, Hodson ME, Pitt TL. Auxotrophy of Pseudomonas aeruginosa in cystic fibrosis. FEMS Microbiol Lett 1992;71:243-6.
19. Hurst JR. Microbial dysbiosis in bronchiectasis. Lancet Respir Med 2014;2:945-7.
20. Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011;10 (Suppl 2):S86-102.